Events during September 2023

CONGRESS 2023 - Recent increases in diphtheria cases in England

27/09/2023
Diphtheria is a potentially fatal disease caused by strains of Corynebacterium diphtheriae, C. ulcerans or C. pseudotubercolosis that express the diphtheria toxin. It can present as a respiratory infection or as non-healing skin wounds. Diphtheria was historically most likely to be caused by C. diphtheriae. It is very rare in England (typically <10 cases per year) due to a successful routine immunisation programme. However, there has been a recent gradual increase in cases over several years, particularly cutaneous infections and those caused by toxigenic C. ulcerans strains (which can be carried by household pets).

In 2022, there was a particulary large increase in diphtheria in England, with 87 cases and 3 deaths. This included 72 toxigenic C. diphtheriae infections in asylum seekers, thought to be aquired during their travel to the UK. Symptoms ranged from severe respiratory diphtheria to cutaneous infections and asymptomatic carriage. Similar increases of C. diphtheriae infections in travelling migrants have been seen in several European countries. Some of these isolates are multidrug resistant, including to macrolides, the default recommendation for treatment, and this will require careful monitoring.

CONGRESS 2023 - Being Patient: Patient experiences of Clostridioides difficile infection and why we should be listening

27/09/2023
Many of us have diagnosed, treated or researched Clostridiodes difficile infection (CDI) for many years and probably know the organism and the disease it produces very well indeed. But how well do we really know it? In truth, we only know this from our own perspective. What is it really like to suffer from CDI? How well do the pathways and guidance we contribute to function in the experience patients?

This talk will focus on patient experiences of CDI, what they can teach us as clinicians and researchers and why involving patients and the public in designing our research and clinical services can help everyone.

CONGRESS 2023 - CE and UKCA certification – what they mean and the implications for pathology

27/09/2023
There are complex regulatory changes taking place across the UK and the EU, which could have a significant impact on laboratory services. This session will cover what you need to know to keep on top of this and know what actions you should be taking for compliance.

CONGRESS 2023 - Help, nothing compatible

27/09/2023
Help, nothing compatible

CONGRESS 2023 - Cutting a clinical career as a scientist in histopathology

27/09/2023
The session will provide an overview of the qualifications that the IBMS offers in those who are carving out a career in Histopathology after they have achieved their specialist level qualification. It will outline the DEP and ASD in Histological Dissection, DEP in Immunocytochemistry and the ASD in Histopathology Reporting qualifications and other related qualifications.

It will explain who these qualifications are aimed and provide an outline of how they are assessed, how candidates can achieve these qualifications and what roles successful candidates can go on to undertake.

CONGRESS 2023 - Ovarian hyperstimulation syndrome (OHSS) – how does the clinical biochemistry laboratory inform clinical decisions?

27/09/2023
Ovarian Hyperstimulation Syndrome is one of the most dangerous complications associated with assisted conception using invitro fertilisation (IVF). If not managed appropriately it can even lead to death of the women developing ovarian hyperstimulation syndrome. Clinical Biochemistry aids significantly in the diagnosis and management of ovarian hyperstimulation syndrome.

This presentation aims to summarise the role of various biochemical parameters that are used routinely in the diagnosis and management of ovarian hyperstimulation syndrome.

CONGRESS 2023 - What is ISO 22367 and how can it help the laboratory comply with the risk requirements of ISO15189

27/09/2023
What is ISO 22367 and how can it help the laboratory comply with the risk requirements of ISO15189

CONGRESS 2023 - Myositis antibodies: are we missing something?

27/09/2023
A myositis-related autoantibody can now be identified in the majority of patients with myositis. They identify homogeneous patient subgroups and are key tools in developing a personalised approach to disease management. There is substantial clinical interest in exploiting myositis autoantibodies as biomarkers, and consequently, a large number of commercial assays have been developed for their detection. Several different commercial assays have now been developed to detect myositis relevant autoantibodies. Many have been developed with the practicalities of clinical practice in mind, offering rapid, affordable, and often multiplex testing. Despite this progress, the perfect system has yet to be realised.

Commercial testing systems do not detect all known myositis relevant autoantibodies and concerns have been raised about the sensitivity and specificity of some assays, including to their ability detect some autoantibodies strongly associated with malignancy and ILD; important causes of mortality and morbidity.

The advantages and disadvantages of different myositis autoantibody testing systems will be discussed. Evidence for the reliability of different types of assays in comparison to immunoprecipitation, as the reference standard, will be reviewed along with testing strategies that make the most of existing technology.

CONGRESS 2023 - It’s life, but not as we know it. Emerging parasitic diseases

27/09/2023
It’s life, but not as we know it. Emerging parasitic diseases

CONGRESS 2023 - Next-generation molecular diagnostics: Leveraging digital technologies to enhance multiplexing in real-time PCR

27/09/2023
Next-generation molecular diagnostics: Leveraging digital technologies to enhance multiplexing in real-time PCR